• Bioretec corrected its June 1 and July 7, 2026, stock option announcements, clarifying that the stated subscription price excludes some options.
• Options granted to US taxpayers use grant-date fair market value to comply with US tax requirements; prices are set separately for each grant.
• These prices have equaled or exceeded the standard subscription price: one-month volume-weighted average share price starting April 29, 2026, with a 20% premium.
• The maximum issuance remains unchanged at 182,970,807 stock options, with maximum dilution of 12% of shares and votes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioretec Oyj published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.